PDCD1 and melanoma: Furthermore, potential studies are set to begin for the purpose of identifying other pediatric patients with different pathologies, including melanoma (NCT04099251 and NCT03553836) or sarcoma (NCT03465592 and NCT03012620), who may experience positive effects of immunotherapy.11 Detailed information on the clinical trials of PD-1/PD-L1 monotherapy is provided in online supplemental table 4.